Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Gaylord Palms Resort & Convention Center

Mar 21, 2016 1:00 PM - Mar 23, 2016 4:30 PM

6000 West Osceola Parkway, Kissimmee, FL 34746

Medical Affairs and Scientific Communications 2016 Annual Forum

Cross-functional forum spotlights topics related to medical communication, medical science liaison, medical call center, and medical writing professionals.

Back to Agenda

Session 6 Track E: Good Publication Practice 3: Ethical and Transparent Publication Practice

Session Chair(s)

Diane Moniz Reed, PharmD

Immuno-Oncology Early Assets, Biomarker Publications and Scientific Content

Bristol-Myers Squibb, United States

Good Publication Practice guideline (GPP3) provides recommendations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. These newly updated recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer reviewed journals and scientific congress presentations. This session will present the updated GPP guidelines and discuss best practices in this highly visible area of pharmaceutical data presentation. It will also share some of the most frequently asked questions that have been received by ISMPP.

Learning Objective :
Discuss why GPP Guidelines are relevant to Medical Writers and all stakeholders involved with industry sponsored presentations and publications
Describe the key guidelines that are considered industry best practice
Explain the main elements of the newly-published GPP3 that are particularly important to Medical Writers
Describe how to access the key Good Publication Practice Guidelines, including GPP3

Speaker(s)

Good Publication Practice 3: Ethical and Transparent Publication Practice Overview and Panel Discussion

Diane Moniz Reed, PharmD

Bristol-Myers Squibb, United States

Immuno-Oncology Early Assets, Biomarker Publications and Scientific Content

Overview and Panel Discussion

Kim Pepitone

Cactus Communications, Inc., United States

Scientific Director

Eileen Girten, MS

Overview and Panel Discussion

Eileen Girten, MS

Pfizer Inc, United States

Director, Medical Writing

Christian Klem

Overview and Panel Discussion

Christian Klem

AstraZeneca Pharmaceuticals, United States

Sr. Director, Global Scientific Publications & Communications, CV

Have an account?